spacer gif spacer gif spacer gif spacer gif spacer gif
QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search    

The fully linked HTML version of this article has now been published.
JCS ePress online publication date 29 Mar 2005
doi: 10.1242/jcs.02308

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcs.02308v1
118/8/1663    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Castro Barros, J.
Right arrow Articles by Marshall, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Castro Barros, J.
Right arrow Articles by Marshall, C. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Research Article

Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton


Joana Castro Barros and Christopher J. Marshall*
* Author for correspondence (e-mail: chris.marshall{at}icr.ac.uk)

Oncogenic transformation often leads to the disruption of the actin cytoskeleton. Activation of the classical Ras-Raf-MEK1/2-ERK1/2 signalling cascade has been implicated in the effects of oncogenes such as Ras and Src on the cytoskeleton. Many of the studies of the effects of oncogenes on the cytoskeleton have made use of chemical inhibitors of MEK1/2 but it is now clear that these inhibitors also inactivate MEK5 in the MEK5-ERK5 MAP kinase pathway raising the possibility that this pathway may also be involved in oncogenic transformation. We therefore investigated whether activation of ERK5 can lead to disruption of the actin cytoskeleton. We show that activation of ERK5 can lead to loss of actin stress fibres, but by a distinct mechanism to ERK1/2. We demonstrate that ERK5 is activated by oncogenic Src as demonstrated by translocation of endogenous ERK5 from the cytoplasm to nucleus and activation of an ERK5-dependent transcriptional reporter and that ERK5 activation is required for Src-mediated transformation. We also show that in Src-transformed cells inhibition of ERK1/2 signalling is not sufficient for reappearance of the actin cytoskeleton and that ERK5 activation contributes to cytoskeletal disruption by Src. Our results suggest that multiple MAP kinase pathways downstream of oncogenes participate in cytoskeletal alterations.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J EndocrinolHome page
K. Ishizawa, N. Dorjsuren, Y. Izawa-Ishizawa, R. Sugimoto, Y. Ikeda, Y. Kihira, K. Kawazoe, S. Tomita, K. Tsuchiya, K. Minakuchi, et al.
Inhibitory effects of adiponectin on platelet-derived growth factor-induced mesangial cell migration
J. Endocrinol., August 1, 2009; 202(2): 309 - 316.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
E. K. Hoffmann, I. H. Lambert, and S. F. Pedersen
Physiology of Cell Volume Regulation in Vertebrates
Physiol Rev, January 1, 2009; 89(1): 193 - 277.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
V. Arnoux, M. Nassour, A. L'Helgoualc'h, R. A. Hipskind, and P. Savagner
Erk5 Controls Slug Expression and Keratinocyte Activation during Wound Healing
Mol. Biol. Cell, November 1, 2008; 19(11): 4738 - 4749.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
M. Schramp, O. Ying, T. Y. Kim, and G. S. Martin
ERK5 promotes Src-induced podosome formation by limiting Rho activation
J. Cell Biol., October 22, 2008; 181(7): 1195 - 1210.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
J. Park, C. Will, B. Martin, L. Gullotti, N. Friedrichs, R. Buettner, H. Schneider, S. Ludwig, and V. Wixler
Deficiency in the LIM-only protein FHL2 impairs assembly of extracellular matrix proteins
FASEB J, July 1, 2008; 22(7): 2508 - 2520.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
H. de Martimprey, J.-R. Bertrand, A. Fusco, M. Santoro, P. Couvreur, C. Vauthier, and C. Malvy
siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma
Nucleic Acids Res., January 17, 2008; 36(1): e2 - e2.
[Abstract] [Full Text] [PDF]

Home page
 Eukaryot CellHome page
A. W. Truman, S. H. Millson, J. M. Nuttall, V. King, M. Mollapour, C. Prodromou, L. H. Pearl, and P. W. Piper
Expressed in the Yeast Saccharomyces cerevisiae, Human ERK5 Is a Client of the Hsp90 Chaperone That Complements Loss of the Slt2p (Mpk1p) Cell Integrity Stress-Activated Protein Kinase
Eukaryot. Cell, November 1, 2006; 5(11): 1914 - 1924.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. E. Schweppe, T. H. Cheung, and N. G. Ahn
Global Gene Expression Analysis of ERK5 and ERK1/2 Signaling Reveals a Role for HIF-1 in ERK5-mediated Responses
J. Biol. Chem., July 28, 2006; 281(30): 20993 - 21003.
[Abstract] [Full Text] [PDF]


© The Company of Biologists Ltd 2005